Zacks Small-Cap Research repeats its valuation on Tiziana Life Sciences as company starts nasally administered Foralumab trial for SPMS
Tiziana Life Sciences is advancing three candidates for a variety of indications in autoimmune disease, cancer and coronavirus (COVID-19) Tiziana announced, on May 25, it had begun treating a first patient with secondary progressive multiple sclerosis (SPMS) in a trial using nasally administered Foralumab - its fully-human anti-CD3 monoclonal antibody
Zacks Small-Cap Research has put out a note on drug developer Tiziana Life Sciences PLC (NASDAQ:TLSA) (LON:TILS), which it started covering in April this year, repeating its valuation of US$7.50 per ADR share, compared to a current price of US$2.37.
25 May 2021 | 09:51am
StockMarketWire.com - Inflammatory diseases and cancer focused Tiziana Life Sciences said the first patient with secondary progressive multiple sclerosis was dosed in a treatment trial.
The trial was testing nasally administered Foralumab, a fully human anti-CD3 monoclonal antibody, at the Brigham and Women s Hospital, Harvard Medical School, Boston, MA.
This clinical study would continue for six months to evaluate routine safety, tolerability, and neurological behaviours.
It also would examine microglial activation, immunological and neurodegenerative markers to assess clinical responses following the treatment regimen.
At 9:51am: [LON:TILS] Tiziana Life Sciences Plc share price was 0p at 92p
This is the first time a nasally administered antibody has been given to a patient with SPMS
Tiziana Life Sciences PLC (LON:TILS, NASDAQ:TLSA) said it has begun treating a patient with secondary progressive multiple sclerosis using nasally-administered Foralumab, the company’s fully-human anti-CD3 monoclonal antibody.
The drug will be provided under the Food & Drug Administration’s individual patient expanded access protocol overseen by researchers at the Brigham and Women s Hospital (BWH), Harvard.
This is the first time a nasally administered antibody has been given to a patient with SPMS.
Sufferers of multiple sclerosis have limited treatment options with Tysabri, sold by Biogen Inc (NASDAQ:BIIB), one of the few drugs offering relief.